NEU neuren pharmaceuticals limited

Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-117

  1. 6,551 Posts.
    lightbulb Created with Sketch. 1857
    FDA bloody mindedness or corruption are my only concerns. Therefore I am (irrationally perhaps) nervous and will be until the decision.
    I don't think LILAC will be a problem (although we perhaps need HT to refresh us on that), because Acadia have used data from the extension trials in support of the application. They would hardly do that (with confidence) if there were negative aspects from them.

    [I am tipping approval early morning our time (27th US time) because of the Rare Diseases Day (as has been discussed here) Would be extremely appropriate].
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.54
Change
0.100(0.80%)
Mkt cap ! $1.559B
Open High Low Value Volume
$12.44 $12.73 $12.13 $11.07M 885.6K

Buyers (Bids)

No. Vol. Price($)
1 1215 $12.52
 

Sellers (Offers)

Price($) Vol. No.
$12.54 804 1
View Market Depth
Last trade - 16.10pm 20/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.